Quick Answer
Whitehawk Therapeutics, Inc. reported Total Revenue of $7.14 million for fiscal year 2025.
Whitehawk Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $7.14M | -72.5% |
| 2024 | $25.98M | +6.7% |
| 2023 | $24.35M | +60.1% |
| 2022 | $15.22M | +8.7% |
| 2021 | $14.00M | +0.0% |
| 2020 | $14.00M | — |
| 2019 | $0.00 | -100.0% |
| 2018 | $20.16M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | -100.0% | — |
| June 30, 2025 | $0.00 | -100.0% | -100.0% |
| March 31, 2025 | $7.14M | +33.5% | -0.9% |
| September 30, 2024 | $7.21M | +21.0% | +16.7% |
| June 30, 2024 | $6.18M | -0.4% | +15.4% |
| March 31, 2024 | $5.35M | -8.8% | -10.2% |
| September 30, 2023 | $5.96M | +40.4% | -3.9% |
| June 30, 2023 | $6.20M | +80.4% | +5.7% |
- Whitehawk Therapeutics, Inc. showed a decrease of -72.5% in Total Revenue compared to the prior fiscal year.
- Over the 2018–2025 period, Whitehawk Therapeutics, Inc.’s total revenue has declined by 64.6% (from $20.16 million to $7.14 million).
- The most recent figure is from Whitehawk Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: